BiomX Inc. has presented a corporate update highlighting its clinical-stage programs aimed at addressing the pressing issue of antibiotic resistance. The company focuses on phage therapy, a promising approach for treating persistent infections. Key developments include positive Phase 2 data for BX211 in treating _S. aureus_ infections, demonstrating sustained ulcer reduction and superior recovery outcomes in bone-depth ulcers. Additionally, BX004 has shown positive Phase 1b/2a results in cystic fibrosis patients with _P. aeruginosa_ infections, indicating sputum culture conversion, improved lung function, and bacterial reduction, with an ongoing Phase 2b study. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.